Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H27N5O21P4 |
Molecular Weight | 773.3229 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(=O)N(C=C1)[C@H]2C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)N4C=CC(=O)NC4=O)O2
InChI
InChIKey=FPNPSEMJLALQSA-MIYUEGBISA-N
InChI=1S/C18H27N5O21P4/c19-11-1-3-22(17(28)20-11)13-5-8(24)9(40-13)6-38-45(30,31)42-47(34,35)44-48(36,37)43-46(32,33)39-7-10-14(26)15(27)16(41-10)23-4-2-12(25)21-18(23)29/h1-4,8-10,13-16,24,26-27H,5-7H2,(H,30,31)(H,32,33)(H,34,35)(H,36,37)(H2,19,20,28)(H,21,25,29)/t8-,9+,10+,13+,14+,15+,16+/m0/s1
Denufosol is a novel second-generation, metabolically stable, selective P2Y(2) receptor agonist. As ion channel regulator denufosol corrects the ion transport defect and increases the overall mucociliary clearance in cystic fibrosis (CF) lung disease by increasing chloride secretion, inhibiting sodium absorption, and increasing ciliary beat frequency in the airway epithelium independently of cystic fibrosis transmembrane conductance regulator genotype. Denufosol improved lung function relative to placebo in cystic fibrosis patients with normal to mildly impaired lung function. The drug half-life is 25 hours in ex vivo CF sputum and 3 hours when added in vitro to human respiratory epithelial cultures. Denufosol has been generally well-tolerated in healthy volunteers and patients with cystic fibrosis. The most common adverse events were in the respiratory system, with cough having the highest frequency.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21169471
60 mg three times daily
Route of Administration:
Respiratory
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C78273
Created by
admin on Fri Dec 15 16:21:49 GMT 2023 , Edited by admin on Fri Dec 15 16:21:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8491
Created by
admin on Fri Dec 15 16:21:49 GMT 2023 , Edited by admin on Fri Dec 15 16:21:49 GMT 2023
|
PRIMARY | |||
|
5PC250KSSH
Created by
admin on Fri Dec 15 16:21:49 GMT 2023 , Edited by admin on Fri Dec 15 16:21:49 GMT 2023
|
PRIMARY | |||
|
DB04983
Created by
admin on Fri Dec 15 16:21:49 GMT 2023 , Edited by admin on Fri Dec 15 16:21:49 GMT 2023
|
PRIMARY | |||
|
100000177262
Created by
admin on Fri Dec 15 16:21:49 GMT 2023 , Edited by admin on Fri Dec 15 16:21:49 GMT 2023
|
PRIMARY | |||
|
DTXSID50870235
Created by
admin on Fri Dec 15 16:21:49 GMT 2023 , Edited by admin on Fri Dec 15 16:21:49 GMT 2023
|
PRIMARY | |||
|
211448-85-0
Created by
admin on Fri Dec 15 16:21:49 GMT 2023 , Edited by admin on Fri Dec 15 16:21:49 GMT 2023
|
PRIMARY | |||
|
CHEMBL507282
Created by
admin on Fri Dec 15 16:21:49 GMT 2023 , Edited by admin on Fri Dec 15 16:21:49 GMT 2023
|
PRIMARY | |||
|
C78118
Created by
admin on Fri Dec 15 16:21:49 GMT 2023 , Edited by admin on Fri Dec 15 16:21:49 GMT 2023
|
PRIMARY | |||
|
DENUFOSOL
Created by
admin on Fri Dec 15 16:21:49 GMT 2023 , Edited by admin on Fri Dec 15 16:21:49 GMT 2023
|
PRIMARY | |||
|
9875516
Created by
admin on Fri Dec 15 16:21:49 GMT 2023 , Edited by admin on Fri Dec 15 16:21:49 GMT 2023
|
PRIMARY | |||
|
m4168
Created by
admin on Fri Dec 15 16:21:49 GMT 2023 , Edited by admin on Fri Dec 15 16:21:49 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)